Latest news with #RedwoodCity-based
San Francisco Chronicle
27-05-2025
- Business
- San Francisco Chronicle
Salesforce agrees to $8 billion tech acquisition
Salesforce has agreed to buy cloud data firm Informatica for around $8 billion. San Francisco-based Salesforce, the city's largest private employer, is paying an approximately 11% premium over Redwood City-based Informatica's Friday closing price. Salesforce said the deal would enhance its data compliance and security products. It plans to integrate Informatica's tech stack including data integration, governance and other tools into its Agentforce AI products. The deal is set to close in early 2027, and subject to regulatory approval. 'This is a transformational step in delivering enterprise-grade AI that is safe, responsible, and deeply integrated with the world's data,' Salesforce CEO Marc Benioff said in a statement. 'We have a shared vision for how we can help organizations harness the full value of their data in the AI era,' said Informatica CEO Amit Walia in a statement. Informatica shares were up 6% on Tuesday to a market capitalization of $7.2 billion at market close. Salesforce shares rose 1.49% on Tuesday to a market capitalization of $265.6 billion at market close.
Yahoo
27-05-2025
- Business
- Yahoo
Salesforce Just Dropped $8 Billion -- And It's Not on AI Hype
Salesforce (NYSE:CRM) is going all in on data. The company just struck an $8 billion deal to acquire Informatica (NYSE:INFA), offering $25 per share in cash a move aimed squarely at bolstering its AI-fueled data ambitions. The deal is expected to close in early fiscal 2027 and will be funded with a mix of cash and new debt. It's a comeback story, too: Salesforce had previously walked away from Informatica just over a year ago, but renewed talks accelerated recently as the company doubled down on scaling its Data Cloud unit. Informatica, long seen as a takeover target, helps businesses manage complex cloud data directly competing with Salesforce's own MuleSoft. Salesforce President and COO Robin Washington didn't mince words: this is a decisive move designed to drive AI-driven growth. And it's one of Salesforce's largest acquisitions to date. Informatica stock jumped 5.7% in premarket trading at 9.04am, while Salesforce ticked up 0.68%. The Redwood City-based data player has seen its market cap shrink 13% this year, but still holds weight with big-name backers like Permira (32%) and CPPIB (25%). Both firms are poised to exit after taking Informatica private in 2015, then guiding its 2021 IPO comeback. Bloomberg Intelligence analysts say the deal shows CEO Marc Benioff's clear intent: go deeper into data infrastructure before the AI data arms race gets even hotter. But not everything is smooth sailing. Informatica and MuleSoft serve similar functions and that overlap could raise eyebrows in Washington. Regulatory scrutiny is a real possibility, especially as Salesforce continues stitching together its software empire. Execution risk also looms large: integrating two massive data platforms won't be plug-and-play. Still, if Salesforce can pull this off, it could unlock a major advantage in AI-based enterprise solutions. The real question: can Benioff extract meaningful growth from this deal before competition or regulators catch up? This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
27-05-2025
- Business
- Yahoo
Salesforce Just Dropped $8 Billion -- And It's Not on AI Hype
Salesforce (NYSE:CRM) is going all in on data. The company just struck an $8 billion deal to acquire Informatica (NYSE:INFA), offering $25 per share in cash a move aimed squarely at bolstering its AI-fueled data ambitions. The deal is expected to close in early fiscal 2027 and will be funded with a mix of cash and new debt. It's a comeback story, too: Salesforce had previously walked away from Informatica just over a year ago, but renewed talks accelerated recently as the company doubled down on scaling its Data Cloud unit. Informatica, long seen as a takeover target, helps businesses manage complex cloud data directly competing with Salesforce's own MuleSoft. Salesforce President and COO Robin Washington didn't mince words: this is a decisive move designed to drive AI-driven growth. And it's one of Salesforce's largest acquisitions to date. Informatica stock jumped 5.7% in premarket trading at 9.04am, while Salesforce ticked up 0.68%. The Redwood City-based data player has seen its market cap shrink 13% this year, but still holds weight with big-name backers like Permira (32%) and CPPIB (25%). Both firms are poised to exit after taking Informatica private in 2015, then guiding its 2021 IPO comeback. Bloomberg Intelligence analysts say the deal shows CEO Marc Benioff's clear intent: go deeper into data infrastructure before the AI data arms race gets even hotter. But not everything is smooth sailing. Informatica and MuleSoft serve similar functions and that overlap could raise eyebrows in Washington. Regulatory scrutiny is a real possibility, especially as Salesforce continues stitching together its software empire. Execution risk also looms large: integrating two massive data platforms won't be plug-and-play. Still, if Salesforce can pull this off, it could unlock a major advantage in AI-based enterprise solutions. The real question: can Benioff extract meaningful growth from this deal before competition or regulators catch up? This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Journals
09-05-2025
- Health
- Business Journals
Bone Health Technologies launches OsteoBoost vibrating belt to combat loss of bone density
From the San Francisco Business Times. One of the most debilitating and potentially deadly effects of aging is the loss of bone density, but a Bay Area startup has launched a unique device that a study showed can help slow that process. Called OsteoBoost, the device is a vibrating belt that sends "low-amplitude, high-frequency" vibrations to the hips and spine, according to a de novo approval that the Food and Drug Administration that was granted early last year. The belt is designed for postmenopausal women with low bone density, or osteopenia — a precursor to osteoporosis — and can be worn throughout the day without impeding normal daily activities like walking. The startup was developed by Redwood City-based Bone Health Technologies, a startup that was spun out of a San Francisco-based medical device incubator called TheraNova in 2018. It's one of a handful of companies focused on addressing women's health issues, and has raised $11 million from investors including Esplanade Ventures, Berkeley Catalyst Fund and Terumo Medical. Although bone density loss affects all bodies, women are particularly vulnerable due to the impact of menopause, which causes accelerated aging from the rapid decline of the hormone estrogen. Around one-third of people older than 50 are estimated to have osteopenia in the U.S., according to the Cleveland Clinic. "You look in the App Store, for instance, under osteoporosis, there's not much there compared to diabetes or depression or high blood pressure, which, of course, are also very important," Bone Health CEO Laura Yecies said. "I believe this deserves that level of attention, and we shouldn't just accept that older women get frail."
Business Wire
05-05-2025
- Business
- Business Wire
Integrated DNA Technologies Brings Innovation Nexus to San Francisco Bay Area
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Global genomics solutions leader Integrated DNA Technologies (IDT) is investing technological capabilities and resources to launch a new innovation hub and support the Bay Area biotech cluster. Located at IDT's Redwood City site, in lockstep with its research and development (R&D) facility, the innovation nexus will serve as a collaboration center that enables IDT to innovate with regional customers, forge strategic partnerships, and drive R&D initiatives with leading-edge biotechnology companies. 'The installation of IDT's Innovation Nexus reflects our commitment to engaging closely with customers and strategic partners, and equipping them with novel solutions, tools of unrivalled quality, and trusted expertise,' said Linda De Jesus. Share The establishment of the innovation nexus is a pivotal element of IDT's strategic roadmap, aimed at acquiring emerging and transformative synthesis technologies ranging from novel chemistries, enzymatic synthesis, and alternative platforms, and driving market growth in precision oncology through advanced next generation sequencing (NGS) applications. Today, the company's NGS portfolio is comprised of xGen™ offerings which include standalone library preparation, target enrichment and normalization chemistries, as well as IDT Archer connected NGS solutions with end-to-end assay platforms, including secondary analysis capabilities and seamless tertiary software integrations. These differentiated solutions have been indispensable to cancer researchers, who rely on strong cancer insights, including both high-quality sequencing and data interpretation. 'The installation of IDT's Innovation Nexus reflects our commitment to engaging closely with customers and strategic partners, and equipping them with novel solutions, tools of unrivalled quality, and trusted expertise,' said Linda De Jesus, VP/GM Global Head of Commercial at Integrated DNA Technologies. 'Building off of our strong foundation in oligo synthesis technologies, IDT today is more than oligos, and we're proud of the evolution we're making to continually innovate with customers, to bring them high-quality technical capabilities and deep scientific knowledge.' The IDT Innovation Nexus complements IDT's rich legacy of innovation, which stems from its origins in Coralville, Iowa. Today, the company's Coralville headquarters remain a center of innovation with its oligo synthesis capabilities, which the company continually optimizes for high-throughput approaches. The Redwood City-based Innovation Nexus also welcomes a new IDT leader with more than a decade of experience who will spearhead the transformation and adoption of new technologies to meet customer needs. The newly created position will oversee a team of scientific experts in transforming IDT's technical capabilities, with a dedicated focus on R&D efforts that will build upon IDT's legacy portfolio and proven expertise in oligo synthesis technologies. To learn how IDT's innovative genomic solutions and bespoke capabilities are accelerating the world's greatest scientific breakthroughs, click here. About IDT Building from a strong foundation of innovation, expertise, and reliability, Integrated DNA Technologies (IDT) has evolved from an oligo manufacturer to a leading genomics provider. We work shoulder-to-shoulder with scientific and global health partners to enable genomics breakthroughs at scale. Our vision of enabling researchers to rapidly move from the lab to life-changing advances reflects our ongoing commitment to a healthier, brighter future for all. IDT is proud to be part of Danaher, a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health. For more information about IDT, visit and follow the company on LinkedIn, X, Facebook, YouTube, and Instagram. Disclaimer: RUO — For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.
